Fierce Pharma2h
In UK, it's strike 2 for Alzheimer's treatments from Lilly and Biogen/Eisai
England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...
STAT2h
We’re reading about an FDA quality lab lease, Marty Makary’s confirmation hearing, and more
The Trump Administration reversed course on plans to terminate the lease of a major Food and Drug Administration quality lab ...
pharmaphorum5h
NICE agrees to look again at Alzheimer's drug Leqembi
The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...
The Pharma Letter6h
Leqembi to get third NICE appraisal committee meeting
In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...
PharmaTimes8h
Leqembi enters second consultation period following NICE draft guidance update
NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.
Aged Care Insite15h
TGA doubles down on rejection of Alzheimer’s drug
Lecanemab is an antibody infusion therapy, developed by pharmaceutical company Eisai, which has been shown to slow cognitive decline in the early stages of Alzheimer's disease. The drug is ...